Newsight Tech Angels

Overview

An angel investment group specializing in biotechnology and healthcare sectors. Established on June 21, 2022, Newsight Tech Angels is based in Tokyo, Japan. The firm focuses on investing in drug discovery seeds and platform technologies, allocating approximately 60% of its investments to Japanese entities and about 20% to non-Japanese entities. The remaining 20% is directed towards portfolio investments in U.S. angel funds. Beyond financial support, Newsight Tech Angels offers hands-on assistance, facilitating licensing agreements in Asian countries, partnerships with pharmaceutical companies, and venture capital funding to enhance the growth and success of its portfolio companies. In March 2023, the firm invested in TRIO Pharmaceuticals, a U.S.-based drug discovery startup, marking its second investment in a U.S. startup. This investment underscores Newsight Tech Angels' commitment to supporting innovative life sciences and healthcare ventures both domestically and internationally. The firm's mission is to cultivate a dynamic startup ecosystem that transcends national boundaries, aiming to bring high-quality research results to practical use and deliver solutions to patients. By bridging the gap between Japanese startups and global markets, Newsight Tech Angels contributes to the creation of a dynamic ecosystem that fosters innovation and growth in the life sciences and healthcare sectors.

Investment Focus

• Focus on biotechnology and healthcare sectors
• Early-stage companies with innovative drug discovery technologies
• Potential for global market expansion

Portfolio Companies